HCV

Waxman takes aim at Gilead over Sovaldi pricing

Waxman takes aim at Gilead over Sovaldi pricing

By

Longtime industry critic, Congressmen Henry Waxman penned a note to Gilead CEO over the "extraordinarily high cost," of its recently approved HCV treatment Sovaldi.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

By

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Data arm Gilead for next stage of HCV race

Data arm Gilead for next stage of HCV race

By

Sovaldi is already approved for most patients with HCV, but its marketer may have earned itself some breathing room against rivals in the next stage of the all-oral hep. C arms race.

Genotype-1 hep. C race heats up

Genotype-1 hep. C race heats up

By

Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.

As HIV meds mature, Gilead preps for HCV launch

As HIV meds mature, Gilead preps for HCV launch

By

A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.

Shutdown delays some FDA committees

User fees keep the regulator's review process running for some drugs, while others see review dates slip.

BMS, Abbott HCV pill data suggest competition for Gilead

By

Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.

Email Newsletters